Loading
AgomAb Therapeutics NV Stock: price and insider trades · United States
US·Mcap US$428M
3 insiders bought €277k of shares over the last 90 days, the latest filed 09 Oct 2026.
Cluster: 3 buyers in 30 daysAgomAb Therapeutics NV: what insiders have been doing
Every trade that managers of AgomAb Therapeutics NV disclose to SEC (Form 4) is tracked on this page. The last twelve months, up to 18 October 2026, brought 8 filings signed by 3 insiders.
Not one open-market sale was filed. On the buying side, 3 insiders reported 8 purchases totalling €277k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €45k, bought by Knotnerus Tim Jasper and made public on 7 October 2026. On the buying side, the filings list 1 finance chief, 1 senior executive and 1 chief executive among the declarants.
Compared with its exchange (5,808 companies, median 19 filings), a count of 8 filings is below the norm. Since 2026, the database holds 8 purchases and no sales by insiders of the company.
In all, 6 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 9 October 2026, which is 9 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
8
Thresholds
n/a
Buy Volume
€277,130
8 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDavid R. Epstein3 buys
Pierre Thadee Victor Kemula3 buys
Tim Jasper Knotnerus2 buys
Analyst consensus: bullish or bearish?
Analysts rate AgomAb Therapeutics NV Strong Buy (bullish), based on 6 analysts. Average price target: US$37.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.69
Analyst consensus
6 analystsStrong buy
US$28.00Target US$37.67(+333%)US$60.00
Income statement
EBITDA-US$62.3M
Net income-US$62.5M0.0% margin
Valuation
PER (forward)-4.2x
P/Book3.4x
Balance sheet & cash
Market capUS$428M
Total debtUS$1.3M
Free Cash Flow-US$51.7M
Debt / Equity0%
Profitability & ownership
% insiders6.0%
% institutions53.7%
Last declaration on 9 October 2026
Declarations8 total
5,000 shares@ US$8.900.010% mcap34.1% of flowCommon sharesSEC:0001445826-26-000014:0
Canonical exit: 6 Jan 2027 (T+90)
6,000 shares@ US$8.4853.9% of flowCommon sharesSEC:0002120886-26-000001:0
Canonical exit: 3 Jan 2027 (T+90)
5,000 shares@ US$8.7046.1% of flowCommon sharesSEC:0002120886-26-000001:1
Canonical exit: 4 Jan 2027 (T+90)
5,000 shares@ US$8.5749.6% of flowCommon sharesSEC:0001445826-26-000013:0
Canonical exit: 3 Jan 2027 (T+90)
5,000 shares@ US$8.7050.4% of flowCommon sharesSEC:0001445826-26-000013:1
Canonical exit: 4 Jan 2027 (T+90)
3,000 shares@ US$8.6730.3% of flowCommon sharesSEC:0002119332-26-000001:0
Canonical exit: 4 Jan 2027 (T+90)
5,000 shares@ US$8.5749.9% of flowCommon sharesSEC:0002119332-26-000001:1
Canonical exit: 4 Jan 2027 (T+90)
2,000 shares@ US$8.5419.9% of flowCommon sharesSEC:0002119332-26-000001:2
Canonical exit: 4 Jan 2027 (T+90)
8 of 8 declarations
About AgomAb Therapeutics NV
AgomAb Therapeutics NV is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and inflammatory disorders. It is listed on NASDAQ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
